



ig 3. Meto-onalysis of lo- sgional rodiction therapy rom- itzed trials: mortality. DeBoer 50 0.67 0.28, 2.65		Study	N	OR	95% CI					
ig 3. Meto-analysis of lo- gional rodiction therapy ran- tized triols: mortolity. image: bit is a start		DeBoer	50	0.87	0.00 0.65			:		
klefstrom 79 0.17 0.04 0.67 Tramprisch 88 1.25 0.53, 2.95 Blomqvist 99 1.16 0.50, 2.70 Hayat 112 1.53 0.70, 3.37 Gervasio 112 1.11 0.51, 2.43 Muss 159 0.81 0.43, 1.50 Schmoor 199 0.72 0.32, 1.67 Griem 219 0.83 0.49 NdArdle 219 0.83 0.49 Veloz-Garcia 239 0.70 0.42, 1.17 Martinez 241 1.12 0.67, 1.87 Olson 312 1.01 0.65, 1.58 Ragaz 318 0.66 0.42, 1.02 Tennvall-Nittby 768 0.96 0.71, 1.30 Overgaard(TAM) 1375 0.73 0.61, 0.98										\rightarrow
Tramprisch 88 1.25 0.53, 2.95 Blomqvist 99 1.16 0.50, 2.70 Hayat 112 1.53 0.70, 3.37 Gervasio 112 1.11 0.51, 2.43 Muss 159 0.81 0.43, 1.50 Schmoor 199 0.72 0.32, 1.67 ogional radiation therapy ran- nized trials: mortality. Marchle 219 0.83 0.49, 1.43 Weiz-García 239 0.70 0.42, 1.17 0.66, 1.99 0.12 Martlinez 241 1.12 0.65, 1.58 0.61, 0.42 0.63 Ragaz 318 0.66 0.42, 1.02 0.000 0.000 0.61, 0.93 Overgaard(TAW) 1375 0.75 0.61, 0.88 0.61 0.61								-		
Blomqvist 99 1,16 0,50,2,70 Hayat 112 1,53 0,70,3,37 Gervasio 112 1,11 0,61,2,43 Muss 159 0,81 0,43,1,50 Schmoor 199 0,72 0,32,1,67 Griem 218 1,17 0,68,1,99 McArdle 219 0,68 0,49,1,43 Velez-Garcia 239 0,70 0,42,1,17 Martinez 2,111 0,65,1,58 Ragaz 318 0,66 0,42,1,02 Tennvall-Nittby 768 0,76 0,61,0,23 Overgaard(TAM) 1375 0,75 0,61,0,93 Overgaard(CME) 1706 0,73 0,61,0,88		Tramprisch						-		1.2.3
Hayat 112 1.53 0.70, 3.37 Gervasio 112 1.11 0.51, 2.43 Muss 159 0.81 0.43, 1.50 Schmoor 199 0.72 0.32, 1.67 Griem 218 1.17 0.66, 1.99 MacArdle 219 0.83 0.49, 1.43 Valez-Garcia 239 0.70 0.42, 1.17 Martinez 241 1.12 0.65, 1.58 Ragaz 138 0.66 0.42, 1.02 Tennvall-Nittby 768 0.96 0.71, 1.30 Overgaard(TAM) 1375 0.73 0.61, 0.98		Blomgvist	99	1.16				:	•	\rightarrow
ig 3. Meto-analysis of lo- gional rodiction therapy ran- tized triols: mortolity. 0 112 1.11 0.51, 2.43		Hayat	112	1.53			1		11000	~
Muss 159 0.81 0.43, 1.50 Schmoor 199 0.72 0.32, 1.67 ig 3. Meto-analysis of lo- sgional radiation therapy ran- nized trials: mortality. Griem 219 0.68, 1.99 MaArcile 219 0.82, 0.42, 1.17 0.66, 1.43		Gervasio	112	1.11				:		~
g 3. Meto-analysis of lo- egional rodiction therapy ron- nized trials: mortality. Schmoor 199 0.72 0.32, 1.67 March 2 218 1.17 0.68, 1.99		Muss	159	0.81						>
g 3. Meto-analysis of lo- gional rodition therapy ran- nized trials: mortality. Griem 218 1.17 0.68, 1.99 MGArdle 219 0.63 0.49, 1.43		Schmoor	199	0.72		-		12		10.000
Agencial robulation merepy run Velez-García 239 0.70 0.42, 1.12 mized triols: mortolity. Martínez 241 1.12 0.67, 1.87 Olson 312 1.01 0.65, 1.58 Ragaz 318 0.66 0.42, 1.02 Tennvall-Nittby 768 0.96 0.71, 1.30 Overgaard(TAM) 1375 0.75 0.61, 0.93	Fig 3. Meta-analysis of lo-		218	1.17						
Vel2-GarCia 239 0.70 0.42, 1.17 Martinez 241 1.12 0.67, 1.87 Olson 312 1.01 0.65, 1.58 Ragaz 318 0.66 0.42, 1.102 Tennvall-Nittby 768 0.96 0.71, 1.30 Overgaard(TAM) 1375 0.75 0.61, 0.89	regional radiation therapy ran-		219	0.83	0.49, 1.43					
Martinez 241 1.12 0.67, 1.87 Olson 312 1.01 0.65, 1.58 Ragaz 318 0.66 0.42, 1.02 Tennvall-Nittby 768 0.96 0.71, 1.30 Overgaard(TAM) 1375 0.75 0.61, 0.93 Overgaard(CMF) 1708 0.73 0.61, 0.89	mized trials: mortality		239	0.70	0.42, 1.17				-	_
Ragaz 318 0.66 0.42, 1.02 Tennvall-Nittby 768 0.96 0.71, 1.30 Overgaard(TAM) 1375 0.75 0.61, 0.93 Overgaard(CMF) 1708 0.73 0.61, 0.89	and more more any.		241	1.12	0.67, 1.87					
Tennvall-Nittby 768 0.96 0.71, 1.30 Overgaard(TAM) 1375 0.75 0.61, 0.93 Overgaard(CMF) 1708 0.73 0.61, 0.89				1.01	0.65, 1.58		_	S		
Overgaard (TAM) 1375 0.75 0.61, 0.93 Overgaard (CMF) 1708 0.73 0.61, 0.89			318	0.66						
Overgaard(CMF) 1708 0.73 0.61, 0.89			768	0.96	0.71, 1.30					
			1375	0.75						
Random Effects OR = 0.83 95% CI = 0.74, 0.94		Overgaard(CMF)	1708	0.73	0.61, 0.89	1100	-			
		Random Effects OR	= 0.83	95% CI =	= 0.74, 0.94	(million)	100	<u>ج</u>		
						4	-	¥		












Table 2		and the second second		en Antonio de la composición de la composi Antonio de la composición
Efficacy of radiation	n in preventing ax	illary recurrences for	r patients with clinic	ally negative axilla
Series	Number of patients	Radiation of level III/SCF	Follow-up	Regional recurrence rate
Haffty [23]	327	Yes	5-year rate	3%
Recht [27]	9	Yes	77 months	2.1%
Wazer [28]	73	Yes	54 months	1%
Wong [29]	92	No	50 months	1%
Halverson [24]	75	Varied	Not provided	2.7%
Zurrida [30]	221	Yes	42 months	0.5%
Hoebers [25]	105	Yes	5-year rate	2%
Kuznetsova [26]	456	Yes	52 months	0%












False negative rate = FN/FN + TP Calculated according to completion AND


False-negative rates in series with sentinel lymph node surgery followed by completion axillary dissection


Series	Total no. of cases	No. of cases with $+LN$	False-negative rate
Krag [7]	443	114	11.4%
Tafra [10]	535	140	13%
Veronesi [11]	376	180	6.7%
McMasters [8]	2148	Not reported	8%
Begkvist [3]	450	184	11%
O'Hea [9]	60	23	13%
Dupount [4]	555	114	4%
Hill [6]	458	47	10.6%
Giuliano			
Early series [1]	174	42	11.9%
Later series [5]	107	42	0%
















	AND (n=213)	SNB(n=180)
Pain	23%	7.8%
Lymphedema	7.1%	1.1%
Numbness	24.4%	3.9%
Strength loss	26.3%	3.9%
ROM	18%	6%








Outcome A	ND VS.	SINB	
Recurrence	AND	SNB	
Axilla	0	0	
Supraclavicular	2	0	
Breast	1	1	
Contralateral breas	st 2	3	
Distant	10	6	
Death	(and a start a fai	and the second	
Breast Cancer	2	1	
Other	4	1	
* Median follow-up = 46 mo	nths		


AND compared to SNB: Side Effects (24 mos)


Mobility	AND (n=100)	SN (n=100)
80 - 100 %	79	100
Swelling (circun	nference)	
No difference	25	93
< 1 cm	38	6
1 – 2 cm	25	1.
> 2 cm	12	0
	Veronesi et a	I NEJM – 349: 546, 2003


Ou	tcome ANI	D vs.	SNB	
		AND	SNB	
Recurr	ence			
	Axilla	0	0	
	Supraclavicular	2	0	
	Breast	1	1	
	Contralateral breast	2	3	
	Distant	10	6	
Death	and the second and a second	AN PARA		
	Breast Cancer	2	1	
	Other	4	1	
* Media	an follow-up = 46 months			
Subala Energy	Veronesi et al NEJM – 3	49. 546 2003	and the second second	
		-0. 040, 2003		


	ND comp Side Effec		nos)	
Pain				
	No	61	92	
	Sporadic	34	7	
Service and Service	Continuous	5	1	
Parest	hesias			
	No	32	99	
	Yes	68	1	
	Veronesi et al NEJN	Л — 349: 546, 20	003	
























Changes to AJCC Staging


• Micrometastases are distinguished from isolated tumor cells on the basis of size and histologic evidence of malignant activity.


Identifiers have been added to indicate the use of sentinel lymph node dissection and


immunohistochemical or molecular techniques.


• Microscopic involvement of the internal mammary nodes detected by sentinel lymph node dissection is classified as N1.
















NCCN®	Practice Guidelines in Oncology – v.3.2003	Invasive Breast Cancer	Guidelines Index Breast Cancer TOC Staging, MS, References
		AXILLARY DISSECTION	
axillary lymp whom the se those with se may be cons nodes only if Sentinel lym	h node dissection, pati lection of adjuvant sys erious comorbid condit idered optional. The ax f there is gross disease ph node biopsy may be sentinel node team and	monstrating superior survival from the pe ients who have particularly favorable tum temic therapy is unlikely to be affected, f tions, the performance of axillary lymph r cillary dissection should be extended to in apparent in the level I or II nodes. e considered an option (category 2B) if th d the patient is an appropriate sentinel lym	nors, patients for for the elderly, or node dissection nclude level III nere is an














Alberta Guidelines: Contraindications

- Clinically positive axillary nodes
- Distant metastases
- Locally advanced or inflammatory
- Previous axillary dissection
- Previous breast surgery eg. Reduction
- Previous RT
- Pregnancy
- Allergy to dye

SNB in Lobular carcinoma						
	Table 2. Pathologic Results for All Lymph Nodes (Including Axillary Sentinel Lymph Nodes)					
Variable	DIC (<i>n</i> = 208 patients)	LIC (<i>n</i> = 35 patients)	<i>P</i> value (chi- square)			
Mean ± SD no. of lymph nodes removed	9.5 ± 3.4	9.8 ± 3.7	NS			
No. of patients with involved lymph nodes (%)	85 (40.8)	11 (31.4)	NS			
		LIC: lobular i	l invasive carcinoma; nvasive carcinoma; SD: riation; NS: not			
sse et al, Cancer 100, 200)4					

